Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Position Boosted by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC raised its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 26.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,846 shares of the company’s stock after acquiring an additional 2,867 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Deciphera Pharmaceuticals were worth $507,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in DCPH. BNP Paribas Arbitrage SA lifted its holdings in shares of Deciphera Pharmaceuticals by 30.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,866 shares of the company’s stock valued at $325,000 after buying an additional 2,055 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Deciphera Pharmaceuticals by 32.6% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,510 shares of the company’s stock valued at $787,000 after buying an additional 5,291 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 16.7% during the 2nd quarter. Citigroup Inc. now owns 116,523 shares of the company’s stock valued at $4,266,000 after buying an additional 16,655 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Deciphera Pharmaceuticals by 5.1% during the 2nd quarter. Swiss National Bank now owns 88,900 shares of the company’s stock valued at $3,255,000 after buying an additional 4,300 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 12.1% during the 2nd quarter. American Century Companies Inc. now owns 295,201 shares of the company’s stock valued at $10,807,000 after buying an additional 31,842 shares during the last quarter. 73.67% of the stock is currently owned by institutional investors.

NASDAQ:DCPH traded down $0.79 during trading hours on Friday, reaching $30.96. The company had a trading volume of 4,935 shares, compared to its average volume of 412,131. The stock has a 50-day moving average of $31.30 and a two-hundred day moving average of $36.75. The firm has a market capitalization of $1.80 billion, a PE ratio of -7.06 and a beta of 1.50. Deciphera Pharmaceuticals, Inc. has a one year low of $26.20 and a one year high of $68.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, August 3rd. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.06). The business had revenue of $23.57 million for the quarter, compared to the consensus estimate of $22.25 million. Deciphera Pharmaceuticals had a negative return on equity of 50.07% and a negative net margin of 308.58%. As a group, equities research analysts predict that Deciphera Pharmaceuticals, Inc. will post -4.88 earnings per share for the current year.

Separately, HC Wainwright reduced their price target on Deciphera Pharmaceuticals from $75.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, August 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $67.43.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.

Featured Article: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH).

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.